On the reversal of new oral anti-coagulants: can we simply extrapolate data from the animal models to humans?

被引：7

作者：

Tanaka, K. A. ^{[1
]}

Bolliger, D. ^{[2
]}

机构：

[1] Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA 15260 USA

[2] Univ Basel Hosp, Dept Anaesthesia & Intens Care Med, CH-4031 Basel, Switzerland

来源：

BRITISH JOURNAL OF ANAESTHESIA | 2013年 / 110卷 / 03期

关键词：

PROTHROMBIN COMPLEX CONCENTRATE; DIRECT THROMBIN INHIBITOR; ACTIVATED FACTOR-VII; RECOMBINANT FACTOR VIIA; BLEEDING RISK; DABIGATRAN; THERAPY; ANTICOAGULATION; RIVAROXABAN; COAGULOPATHY;

D O I：

10.1093/bja/aes502

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

引用

页码：329 / 332

页数：4

共 30 条

[1] Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].

Ageno, Walter ;

Gallus, Alexander S. ;

Wittkowsky, Ann ;

Crowther, Mark ;

Hylek, Elaine M. ;

Palareti, Gualtiero .

CHEST, 2012, 141 (02) :E44S-E88S

[2] Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome [J].

Alexander, John H. ;

Lopes, Renato D. ;

James, Stefan ;

Kilaru, Rakhi ;

He, Yaohua ;

Mohan, Puneet ;

Bhatt, Deepak L. ;

Goodman, Shaun ;

Verheugt, Freek W. ;

Flather, Marcus ;

Huber, Kurt ;

Liaw, Danny ;

Husted, Steen E. ;

Lopez-Sendon, Jose ;

De Caterina, Raffaele ;

Jansky, Petr ;

Darius, Harald ;

Vinereanu, Dragos ;

Cornel, Jan H. ;

Cools, Frank ;

Atar, Dan ;

Luis Leiva-Pons, Jose ;

Keltai, Matyas ;

Ogawa, Hisao ;

Pais, Prem ;

Parkhomenko, Alexander ;

Ruzyllo, Witold ;

Diaz, Rafael ;

White, Harvey ;

Ruda, Mikhail ;

Geraldes, Margarida ;

Lawrence, Jack ;

Harrington, Robert A. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08) :699-708

[3] Mechanism of factor VIIa-dependent coagulation in hemophilia blood [J].

Butenas, S ;

Brummel, KE ;

Branda, RF ;

Paradis, SG ;

Mann, KG .

BLOOD, 2002, 99 (03) :923-930

[4] Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents [J].

Crowther, Mark A. ;

Warkentin, Theodore E. .

BLOOD, 2008, 111 (10) :4871-4879

[5] Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].

Eerenberg, Elise S. ;

Kamphuisen, Pieter W. ;

Sijpkens, Meertien K. ;

Meijers, Joost C. ;

Buller, Harry R. ;

Levi, Marcel .

CIRCULATION, 2011, 124 (14) :1573-1579

[6] Update on Antithrombotic Therapy New Anticoagulants [J].

Eikelboom, John W. ;

Weitz, Jeffrey I. .

CIRCULATION, 2010, 121 (13) :1523-1532

[7] Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin [J].

Eisert, Wolfgang G. ;

Hauel, Norbert ;

Stangier, Joachim ;

Wienen, Wolfgang ;

Clemens, Andreas ;

van Ryn, Joanne .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (10) :1885-1889

[8] Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits [J].

Elg, M ;

Carlsson, S ;

Gustafsson, D .

THROMBOSIS RESEARCH, 2001, 101 (03) :159-170

[9] Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor [J].

Elg, M ;

Carlsson, S ;

Gustafsson, D .

THROMBOSIS RESEARCH, 2001, 101 (03) :145-157

[10] Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents [J].

Fukuda, Toshio ;

Honda, Yuko ;

Kamisato, Chikako ;

Morishima, Yoshiyuki ;

Shibano, Toshiro .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) :253-259

← 1 2 3 →